
Oscotec wins FDA nod for anti-resistance cancer trial, drops oral denfivontinib over safety issues
Oscotec is placing its bets on anti-resistance cancer therapies. The Korean biotech received the U.S. FDA green light to go ahead with a phase 1 trial for OCT-598, a dual EP2/EP4 antagonist designed to cut off tumor regrowth signals triggered by cell …